Neuroglee secures $10m funding to advance home-based Alzheimer's treatment

Openspace Ventures led the Series A round. 

Neuroglee Therapeutics, which builds personalised evidence-based digital therapeutics (DTx) and virtual care solutions to treat and manage patients with neurodegenerative diseases, has closed a $10m Series A funding round last 9 September.

The funding injection will enable Neuroglee to launch pioneering virtual neurology clinics for patients diagnosed with mild cognitive impairment related to difficult-to-treat conditions such as Alzheimer's disease, whilst advancing the company's DTx pipeline.

According to Neuroglee Founder and CEO Aniket Singh Rajput, "This funding will be instrumental in facilitating the continued development of Neuroglee's digital therapeutics and virtual clinical services, which combines cognitive rehabilitation strategies and remote care management to help delay or slow the worsening of symptoms in patients with mild cognitive impairment due to Alzheimer’s disease."

Neuroglee and Mayo Clinic are co-developing Neuroglee Connect, a novel clinical care program based on Mayo Clinic's Healthy Action to Benefit Independence & Thinking (HABIT). HABIT is a 10-day in-person program to provide patients and their families with state-of-the-art, evidence-based lifestyle and behavioural treatments for mild cognitive impairment.

Openspace Ventures led the round with participation from EDBI, Mudipharma former CEO Raman Singh, Biofourmis co-founders Kuldeep Singh Rajput and Wendou Niu, and pharmaceutical company Eisai Co.